Loading stock data…
IMRX
$5.37+0.13 (+2.48%)
Market ClosedLast close May 1
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immuneering Corporation in the Healthcare sector is trading at $5.37. The stock is currently 47% below its 52-week high of $10.08, remaining 5.3% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why IMRX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.37
Potential Upside
5%
Whystock Fair Value$5.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$17.00+216.6%
Range$11.00 – $30.00
Fundamentals
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$388.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.64%
Volume
Today's trading volume
647,441
Recent News
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as “extraordinary” early survival results for the company’s lead program, atebimetinib, in first-line pancreatic cancer, and outlined multiple upcoming clinic
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified Buy or Overweight ratings, and the gap between current trading prices and analyst targets ranges from substantial to dramatic. Three Calls, Three Catalysts ... X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3
Immuneering (NASDAQ:IMRX) Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference that the company is focused on improving survival in first-line pancreatic cancer and “beyond,” led by its oral MEK inhibitor candidate atebime
Director of Immuneering Picks Up 1.8% More Stock
Even if it's not a huge purchase, we think it was good to see that Peter Feinberg, the Director of Immuneering...
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition
Immuneering (IMRX) has attracted fresh attention after reporting updated Phase 2a data for atebimetinib in first line pancreatic cancer, showing 64% 12 month overall survival and plans to move into a pivotal Phase 3 trial. See our latest analysis for Immuneering. Despite the strong clinical update, Immuneering’s latest share price of $4.66 comes after a 30 day share price return of a 23% decline and a 7 day share price return of a 30% decline. This contrasts with a very large 1 year total...